The relationship between bone metabolism and primary aldosteronism

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000040809

Enrollment

Unknown

Registered

2020-12-10

Start date

2020-12-09

Completion date

Unknown

Last updated

2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary aldosteronism

Interventions

primary aldosteronism group:Nil

essential hypertension group:Nil

Eligibility

Sex/Gender

All

Age

15 Years to 100 Years

Inclusion criteria

Inclusion criteria: Experimental group: patients diagnosed with primary aldosteronosis (ARR > 50 or with at least one positive diagnostic test: oral high-sodium diet, fluorohydrocortisone test, saline infusion test, and captopril test). Control group: essential hypertension patients with nonfunctional adrenal hyperplasia or nonfunctional adrenal adenoma (EH).

Exclusion criteria

Exclusion criteria: Taking drugs affect bone metabolism (double phosphonic acid salt, and the single resistance, tenet peptide, raloxifene, ever more Finn, corticosteroids, etc.) or combined with other diseases can cause secondary osteoporosis (such as thyroid disease, inflammatory bowel disease, chronic liver disease, disease of grow in quantity of gonad hypofunction, cortisol, primary hyperparathyroidism, rheumatoid arthritis, cancer, osteoarthritis, blood system diseases, etc.).

Design outcomes

Primary

Measure	Time frame
BMD;calcitonin;PTH;BALP;N-MID;PINP;ß-CTx;25-(OH)-D3;PAC;PRA;ARR;	—

Secondary

Measure	Time frame
Plasma cortisol concentration;ACTH;	—

Countries

China

Contacts

Public ContactGuo Ying

Sun Yat-Sen Memorial Hospital

gying@mail.sysu.edu.cn+86 13580328257

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026